U.S. market Closed. Opens in 7 hours 36 minutes

TBIO | Telesis Bio, Inc. Stock Overview

(Stock Exchange: NASDAQ)
Day's Range 1.2800 - 1.4500
52 Week Range 1.2700 - 15.46
Beta 1.75
Implied Volatility 525.13%
IV Rank 100.00%
Day's Volume 420
Average Volume 1,417,879
Shares Outstanding 1,772,950
Market Cap 2,570,778
Sector Healthcare
Industry Medical - Devices
IPO Date 2021-06-18
Valuation
Profitability
Growth
Health
P/E Ratio -0.05
Forward P/E Ratio N/A
EPS -30.42
1YR Price Target N/A
Dividend Yield N/A
Dividend Per Share N/A
Dividend ExDate N/A
Dividend PayDate N/A
Employees 101
Country USA
Website TBIO
Codex DNA, Inc., a synthetic biology company, manufactures and sells synthetic biology instruments, reagents, and associated products and related services, primarily to pharmaceutical and academic laboratories worldwide. Its solutions include BioXp system that empowers researchers to go from a digital DNA sequence to endpoint-ready synthetic DNA; BioXp portal, an online portal that offers an intuitive guided workflow and design tools for building new DNA sequences and assembling them into vectors of choice; BioXp kits that contain building blocks and reagents, including its Gibson Assembly branded reagents, for specific synthetic biology workflow applications; Cloud-based scripts; Benchtop reagents that contain all the reagents necessary to proceed with a specific synthetic biology workflow on the benchtop using products generated on the BioXp system; Biofoundry Services, which enable a customer to order and receive the BioXp system endpoint-ready products, such as genes, clones, cell-free amplified DNA, and variant libraries; and short oligo ligation assembly enzymatic DNA synthesis. It also serves government institutions, contract research organizations, and synthetic biology companies. The company was formerly known as SGI-DNA, Inc. and changed its name to Codex DNA, Inc. in March 2020. Codex DNA, Inc. was incorporated in 2011 and is headquartered in San Diego, California.
TBIO's peers: CLPT, DCTH, RCEL, SRTS, TELA, VMD, XAIR
*Chart delayed
Analyzing fundamentals for TBIO we got that it has weak fundamentals where Valuation is considered to be overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is frighteningly weak. For more detailed analysis please see TBIO Fundamentals page.

Watching at TBIO technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on TBIO Technicals page.
An error has occurred. This application may no longer respond until reloaded. Reload 🗙